Lyophilized formulations of Salinosporamide A

Details Lyophilized formulations of Salinosporamide A Lyophilized formulations of Salinosporamide A

2008-02-04

2010-11-02

Padmanabhan, Sreeni (Department: 1628)

Drug, bio-affecting and body treating compositions

Preparations characterized by special physical form

C514S421000, C514S255060, C514S254110, C548S453000

Reexamination Certificate

active

07824698

ABSTRACT:
Lyophilized formulations comprising Salinosporamide A or analogs thereof are provided. In some aspects, lyophilized formulations comprising Salinosporamide A or analogs thereof and bulking agents are provided. Also provided are methods of lyophilizing Salinosporamide A or analogs thereof. In some aspects, a solvent or co-solvent system is utilized. Also provided are methods of administering Salinosporamide A or analogs thereof to patients.

REFERENCES:
patent: 5008294 (1991-04-01), Neiss et al.
patent: 5445829 (1995-08-01), Paradissis et al.
patent: 5576012 (1996-11-01), Bauer et al.
patent: 5601845 (1997-02-01), Buxton et al.
patent: 5641515 (1997-06-01), Ramtoola
patent: 5653987 (1997-08-01), Modi et al.
patent: 5654286 (1997-08-01), Hostetler
patent: 5667809 (1997-09-01), Trevino et al.
patent: 5683676 (1997-11-01), Akehurst et al.
patent: 5688529 (1997-11-01), Lidgate et al.
patent: 5707615 (1998-01-01), Cardin et al.
patent: 5707641 (1998-01-01), Gertner et al.
patent: 5726181 (1998-03-01), Hausheer et al.
patent: 5733888 (1998-03-01), Carver et al.
patent: 5756764 (1998-05-01), Fenteany et al.
patent: 5874443 (1999-02-01), Kiely et al.
patent: 5886210 (1999-03-01), Rayle et al.
patent: 5922683 (1999-07-01), Or et al.
patent: 6133308 (2000-10-01), Soucy et al.
patent: 6147223 (2000-11-01), Fenteany et al.
patent: 6214862 (2001-04-01), Fenteany et al.
patent: 6271199 (2001-08-01), Brand et al.
patent: 6294560 (2001-09-01), Soucy et al.
patent: 6333358 (2001-12-01), Nakazato et al.
patent: 6335358 (2002-01-01), Fenteany et al.
patent: 6350759 (2002-02-01), Casara et al.
patent: 6458825 (2002-10-01), Fenteany et al.
patent: 6500825 (2002-12-01), Lan et al.
patent: 6506787 (2003-01-01), Fujishita et al.
patent: 6509331 (2003-01-01), Audia et al.
patent: 6566553 (2003-05-01), Soucy et al.
patent: 6645999 (2003-11-01), Schreiber et al.
patent: 6794516 (2004-09-01), Soucy et al.
patent: 6838477 (2005-01-01), Schreiber et al.
patent: 6849743 (2005-02-01), Soucy et al.
patent: 7144723 (2006-12-01), Fenical et al.
patent: 7176232 (2007-02-01), Fenical et al.
patent: 7176233 (2007-02-01), Fenical et al.
patent: 7179834 (2007-02-01), Fenical et al.
patent: 7183417 (2007-02-01), Corey
patent: 7276530 (2007-10-01), Potts et al.
patent: 7276630 (2007-10-01), Dockner et al.
patent: 2001/0051654 (2001-12-01), Elliott et al.
patent: 2003/0157695 (2003-08-01), Fenical et al.
patent: 2004/0132692 (2004-07-01), Sherrill et al.
patent: 2004/0138196 (2004-07-01), Fenical et al.
patent: 2005/0049294 (2005-03-01), Palladino et al.
patent: 2005/0203029 (2005-09-01), Schubert et al.
patent: 2005/0203162 (2005-09-01), Xiao et al.
patent: 2006/0008852 (2006-01-01), Fenical et al.
patent: 2006/0229353 (2006-10-01), Stadler et al.
patent: 2006/0264495 (2006-11-01), Palladino et al.
patent: 2006/0287520 (2006-12-01), Danishefsky et al.
patent: 2007/0004676 (2007-01-01), Palladino et al.
patent: 2007/0155815 (2007-07-01), Fenical et al.
patent: 2007/0161693 (2007-07-01), Corey
patent: 2007/0225350 (2007-09-01), Anderson et al.
patent: 2008/0070273 (2008-03-01), Fenical et al.
patent: 2008/0070969 (2008-03-01), Potts et al.
patent: 2009/0069401 (2009-03-01), Fenical
patent: 2429163 (2002-06-01), None
patent: WO 96/32105 (1996-10-01), None
patent: WO 99/09006 (1999-02-01), None
patent: WO 99/15183 (1999-04-01), None
patent: WO 00/23614 (2000-04-01), None
patent: WO 02/47610 (2002-06-01), None
patent: WO 02/067901 (2002-09-01), None
patent: WO 2004/043374 (2003-11-01), None
patent: WO 2004/071382 (2004-08-01), None
patent: WO 2005/002572 (2005-01-01), None
patent: WO 2005/003137 (2005-01-01), None
patent: WO 2006/028525 (2005-03-01), None
patent: WO 2005/094423 (2005-10-01), None
patent: WO 2005/099687 (2005-10-01), None
patent: WO 2006/005551 (2006-01-01), None
patent: WO 2006/017346 (2006-02-01), None
patent: WO 2006/060609 (2006-06-01), None
patent: WO 2006/060809 (2006-06-01), None
patent: WO 2006/118973 (2006-11-01), None
patent: WO 2007/021897 (2007-02-01), None
patent: WO 2007/033039 (2007-03-01), None
patent: WO 2007/138116 (2007-12-01), None
patent: WO 2008/137780 (2008-11-01), None
BASF, Technical Information, 2004.
Adams, Julian, “Proteasome Inhibitors as New Anticancer Drugs”,Curr. Opin. Oncol., (2002) 14:628.
Adams, et al., “Proteasome Inhibitors: A Novel Class of Potent and Effective Antitumor Agents”,Cancer Res., (1999) 59:2615.
Adams, J., “The Development of Novel Targeted Therapeutics for Treatment of Multiple Myeloma Research Roundtable”,Euro. J. Haematology, (2003) 70:263-272.
Alessandri, et al., “Mobilization of Capillary Endothelium In Vitro Induced by Effectors of Angiogenesis In Vivo”,Cancer Res., (1983) 43(4):1790-1797.
Alm, et al., “Effects of Topically Applied PGF2 and its Isopropylester on Normal and Glaucomatous Human Eyes”,Prog. Clin. Biol. Res., (1989) 312:447-58.
Beers et al. (Eds.),The Merck Manual of Diagnosis and Therapy, 17th Ed. 1999, Merck & Co., pp. 397-398, 948-949, 1916 and 1979-1981.
Beers et al. (Eds.),The Merck Manual of Diagnosis and Therapy, 17th Ed. 1999, The Merck Research Laboratories, Whitehouse Station N.J., pp. 1193-1204. XP002510943.
Bernan, et al., “Marine Microorganisms as a Source of New Natural Products”,Advances in Applied Microbiology, (1997) 43:57-90.
Bhalla, et al., “High-Dose Mitoxantrone Induces Programmed Cell Death or Apoptosis in Human Myeloid Leukemia Cells”,Blood, (1993) 82(10):3133-3140.
Bicknell, et al. (Eds.),Tumour Angiogenesis, Oxford University Press, New York (1997), Table of Contents, pp. 5.
Blum, et al., “Adriamycin: A New Anticancer Drug with Significant Clinical Activity”,Ann Intern Med, (1974) 80(2):249-259.
Blunt, et al., “Marine Natural Products”,Nat. Prod. Rep., (2003) 20:1-48.
Bodart, et al., “Anthrax, MEK and Cancer”,Cell Cycle, (2002) 1:10-15.
Bradley, et al., “Identification of the Cellular Receptor for Anthrax Toxin”,Nature, (2001) 414:225-229.
Bull, et al., “Search and Discovery Strategies for Biotechnology: the Paradigm Shift”,Microbiol. Mol. Biol. Rev., (2000) 64(3):573-606.
Carey, Francis,Organic Chemistry, 2nd ed., McGraw Hill, Inc., New York (1992), pp. 328-331.
Chauhan, et al., “A Novel Orally Active Proteasome Inhibitor Induces Apoptosis in Multiple Myeloma Cells with Mechanisms Distinct from Bortezomib”,Cancer Cell, (2005) 8:407-419.
Chauhan, et al., “A Novel Proteasome Inhibitor NPI-0052 as an Anticancer Therapy,”British Journal of Cancer, (2006) 95(8):961-965.
Cheng, et al., “Arenaric Acid, a New Pentacyclic Polyether Produced by a Marine Bacterium (Actinomycetales)”,J. Nat. Prod., (1999) 62:605-607.
Cheng, et al., “Luisols A and B, New Aromatic Tetraols Produced by an Estuarine Marine Bacterium of the GenusStreptomyces(Actinomycetales)”,J. Nat. Prod., (1999) 62:608-610.
Claverol, et al., “Mapping and Structural Dissection of Human 20 S Proteasome Using Proteomic Approaches”,Mol Cell Proteomics, (2002) 1:567-78.
Colquhoun, et al, “Rapid Characterization of Deep-Sea Actionmycetes for Biotechnology Screening Programmes”,Antonie Van Leeuwenoek, (2000) 77:359-367.
Colquhoun, et al., “Novel Rhodococci and Other Mycolate Actinomycetes From the Deep Sea”,Antonie van Leeuwenhoek, (1998) 74:27-40.
Colquhoun, et al., “Taxonomy and Biotransformation Activites of Some Deep-Sea Actinomycetes”,Extremophiles, (1998) 2:269-277.
Corey et al. “The Structural Requirements for Inhibition of Proteasome Function by the Lactacystin-derived beta-lactone and Synthetic Analogs”,Tetrahedron(1999) 55(11):3305-3316.
Crane, et al., “A Novel Enantioselective Synthetic Route to Omuralide Analogues with the Potential for Species Selectivity in Proteasome Inhibition”,Organic Letters, (2001) 1395-1397.
Cragg, et al. “Chemical Diversity: A Function of Biodiversity”,Trends Pharmacol. Sci., (2002) 23:404.
Crueger, et al. (Eds.)

Affiliated with

Also associated with

Rating

Lyophilized formulations of Salinosporamide A does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Lyophilized formulations of Salinosporamide A, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Lyophilized formulations of Salinosporamide A will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4188772